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In 1997, the first consensus guidelines for haematopoietic
SCT (HSCT) in autoimmune diseases (ADs) were
published, while an international coordinated clinical
programme was launched. These guidelines provided
broad principles for the field over the following decade
and were accompanied by comprehensive data collection
in the European Group for Blood and Marrow Trans-
plantation (EBMT) AD Registry. Subsequently, retro-
spective analyses and prospective phase I/II studies
generated evidence to support the feasibility, safety and
efficacy of HSCT in several types of severe, treatment-
resistant ADs, which became the basis for larger-scale
phase II and III studies. In parallel, there has also been an
era of immense progress in biological therapy in ADs. The
aim of this document is to provide revised and updated
guidelines for both the current application and future
development of HSCT in ADs in relation to the benefits,
risks and health economic considerations of other modern
treatments. Patient safety considerations are central to
guidance on patient selection and HSCT procedural
aspects within appropriately experienced and Joint Accred-
itation Committee of International Society for Cellular
Therapy and EBMT accredited centres. A need for
prospective interventional and non-interventional studies,
where feasible, along with systematic data reporting, in
accordance with EBMT policies and procedures, is
emphasized.
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Introduction
Background
Autoimmune diseases (ADs) are heterogeneous both in
manifestation and severity. Immunosuppressive therapy,
including novel biological therapies, enables short-term
disease control and minimization of organ damage in most
cases, but long-term treatment-free remission and/or
definitive cure remain elusive. Major organ involvement,
rapidly progressing disease and persistent disease activity
result in significant disability, reduction in quality of life
(QoL) and life expectancy. Toxicities of chronic treatment
and the personal and societal costs are considerable. In this
context, haematopoietic SCT (HSCT) has been used in
severe AD for the past 15 years to control otherwise
resistant disease activity, or even cure, by inducing
fundamental immunological changes never previously seen
with other forms of therapy.Received 3 May 2011; revised and accepted 4 July 2011
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The concept of HSCT in severe ADs initially evolved in
animal models,1–7 with the potential benefits in humans
supported by reports of profound clinical response of ADs
to HSCT performed for other conventional indications.8,9
From 1995, the first HSCT procedures specifically for ADs
were performed, and, in 1996, the European Group for
Blood and Marrow Transplantation (EBMT) AD Working
Party (ADWP) was launched.10,11 The collaboration was
progressively built on by active involvement with specialist
European societies working together with the EBMT,
specifically the European League against Rheumatism
and its working groups in Systemic Sclerosis (EUSTAR)
and Lupus Erythematosus (Eurolupus), the European
Crohn’s and Colitis Organization, and the European
Committee for Treatment and Research in Multiple
Sclerosis. Further interactions outside of Europe involved
the Center for International Bone Marrow Transplant
Registry12 and the National Institutes of Health,12,13 along
with large HSCT programmes in the field, such as
Northwestern University, Chicago, and active groups in
Australia, Brazil and China.
A database dedicated to adult and paediatric patients
with AD treated with high-dose chemotherapy and auto-
logous, syngeneic or allogeneic HSCT was created and
EBMT centres were requested to report all procedures with
annual updates. Thereafter, specific data forms were
introduced into the Central EBMT database (http://
www.ebmt.org/4Registry/registry3.html). It is currently
estimated that around 3000 AD patients have now been
treated worldwide by HSCT. Table 1 summarizes the
current EBMT AD Registry as of June 2011 in terms of AD
indications in the adult (X18 years) and paediatric (o18
years) age groups. The majority of adult patients have been
treated with autologous HSCT (n¼ 1090), with donor
HSCT (n¼ 25) comprised of related donor HSCT (n¼ 20,
including two syngeneic HSCT) and unrelated donor
HSCT (n¼ 5). Likewise most paediatric patients also
underwent autologous HSCT (n¼ 119), although donor
HSCT was proportionally more frequent (n¼ 40), with
related donor HSCT (n¼ 24, including two syngeneic
HSCT) and unrelated donor HSCT (n¼ 16). The remainder
of worldwide cases have been reported to the United States-
based CIBMTR, or have been performed in Asia or the
Eastern Mediterranean regions, or are present in other
individual centre registries outside of Europe, such as
Northwestern University, Chicago.12,14–16
Successive analyses of the EBMT database provided
evidence for the feasibility and the toxicity of the HSCT
procedures across a large number of ADs.17,18 Prospective
phase I/II studies were progressively reported across a wide
range of AD, including multiple sclerosis (MS),19–27
systemic sclerosis (SSc),28–31 systemic lupus erythematosus
(SLE),14 rheumatoid arthritis (RA),32–34 juvenile chronic
arthritis (JIA),35–37 Crohn’s disease (CD)38–40 and type 1
diabetes (T1D).41–43 In the most recent general retrospective
analysis, among 900 patients undergoing first autologous
HSCT, the overall 5-year survival was 85%, with 43% PFS.
Outcomes varied with diagnosis, age and centre activity.18
Retrospective analysis of limited numbers of allogeneic
HSCT, including the use of donor T-cell infusions,
confirmed the ability to achieve very prolonged remission,
but with significantly more toxicity and TRM than with
autologous HSCT.44 Other retrospective analyses were used
to support the feasibility, safety and efficacy in specific
ADs, including MS, SSc, SLE, RA, JIA, autoimmune
cytopenias, vasculitis and paediatric diseases.45–54
The results of retrospective and prospective studies were
the basis for randomized phase II/III studies in the major
disease indications: in SSc (ASTIS, http://www.astistrial.
com; ASSIST, http://www.clinicaltrials.gov; SCOT, http://
www.clinicaltrials.gov); in MS (ASTIMS, http://www.
astims.org; MIST (Multiple Sclerosis International Stem
cell Trial), http://www.clinicaltrials.gov); and in CD
(ASTIC, http://www.nottingham.ac.uk/icr/astic/).
Mechanism of action
For many years, the use of HSCT to induce tolerance by
replacing (allogeneic) or resetting (autologous) immune
Table 1 EBMT database of autoimmune diseases, June 2011
Diseases No. of patients
Paediatricsa Adults Total
Auto/Allo Auto/Allo Auto/Allo
Neurological diseases 9/0 493/4 502/4
Multiple sclerosis 7/0 462/3 469/3
Other neurological diseases,
for example, myasthenia
gravis
2/0 31/1 33/1
Connective tissue diseases 29/1 367/1 396/2
Systemic sclerosis 9/0 257/0 266/0
Systemic lupus erythematosus 17/1 78/1 95/2
Polymyositis–
dermatomyositis
0 16/0 16/0
Other connective tissue
disease, including Sjogren’s
disease
2/0 16/0 18/0
Arthritis 62/4 90/2 152/6
Rheumatoid arthritis 1/0 75/2 76/2
Juvenile chronic arthritis 61/3 10/0 71/3
Other arthritis, including
psoriatic
0/1 5/0 5/1
Vasculitis 3/3 26/1 29/4
Haematological 7/21 31/13 38/34
Immune thrombocytopenia 3/1 18/3 21/4
Autoimmune haemolytic
anaemia
1/3 8/2 9/5
Evans’ syndrome 2/10 3/2 5/12
Other haematological,
including pure red/white cell
aplasia
1/7 2/6 3/13
Inflammatory bowel disease 8/5 51/1 59/6
Crohn’s disease 7/1 49/0 56/1
Ulcerative colitis 1/2 1/0 1/3
Other 0/2 1/1 1/3
Type 1 diabetes 10/0 10/0
Others 1/6 22/2 23/8
Total 119/40 1090/24 1209/64
Abbreviation: EBMT¼European Group for Blood and Marrow Trans-
plantation.
aPaediatric¼ less than 18 years old at HSCT.
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responses in patients with ADs by HSCT remained an
attractive prospect,55 arising from genetically prone and
immunized animal models of AD treated with allogeneic,
syngeneic, autologous and pseudo-autologous HSCT.1–7
The preclinical evidence for a graft-vs-autoimmune effect
important in the replacement of a dysfunctional immune
system by allogeneic HSCT has been subsequently sup-
ported by clinical evidence.44,56–60
In autologous HSCT, analysis of the regenerating
adaptive immune system showed normalization of the
restricted T-cell repertoire, with sustained shifts in T- and
B-cell subpopulations from memory to naı¨ve cell dom-
inance, supportive of thymic reprocessing and re-education
of the reconstituting immune system.61,62 In addition,
restoration of normal or raised levels of CD4þ regulatory
T cells with the disappearance of circulating plasmablasts is
reported in JIA,63–65 and unusual CD8þFoxP3þ regula-
tory T-cell subsets, capable of inhibiting the pathogenic T-
cell response to autoepitopes in nucleosomes, are seen in
SLE following autologous HSCT, but not after conven-
tional immunosuppressive therapies.66,67 These results
separated the nonspecific immunosuppressive changes,
observed in both blood and tissue after cytotoxic ther-
apy,62,68 from immune re-educative changes supporting
immune tolerance.69 Other downstream changes, such as
reduction in dermal fibrosis,29,70,71 with increased dermal
microcirculation72,73 and early regression of the extent of
CT scan fibrosis74 in systemic sclerosis were reported.
Advances in biological therapies and other non-HSCT
treatments
The advent of many novel biological therapies improved
outcomes in many ADs in recent years. Nonetheless,
significant numbers of patients fail to respond or develop
resistance to modern biological-based therapies or develop
unacceptable side effects and severe infectious complica-
tions, long-term malignancies or secondary ADs.75–77 In
addition, chronic administration of novel treatments is also
a major socioeconomic challenge. There remains a need for
highly active, but deliverable treatment regimens for
patients with a poor prognosis due to rapidly progressive
and treatment-resistant ADs.
Guidelines’ process and aims
The first guidelines published in 1997 represented a
relatively uniform approach toward developing the field
both within and outside clinical trials, with an emphasis on
registry reporting.11 Further brief, revised recommenda-
tions are included in various iterations of the general
EBMT indications for HSCT.78 The aims of these current
updated guidelines are to support HSCT centres running a
local trial, or dealing with a complex AD patient, and also
to guide health-care administrative bodies and insurance
companies. There is an emphasis on patient safety, with
criteria for selection and HSCT procedural aspects, under-
pinned by a requirement for accreditation of HSCT
programmes by JACIE (Joint Accreditation Committee
of International Society for Cellular Therapy and EBMT)
or equivalent quality management systems, which improve
clinical outcomes in HSCT.79,80 Where possible, inclusion
of patients on prospective clinical studies, ideally
randomized controlled trials, and also prospective non-
interventional studies (in accordance with current EBMT
registry guidelines) is also essential for development of
the field.
Levels of evidence have been inserted according to
the currently accepted EBMT grading system (Tables 2a
and b). Each disease-specific panel session workshop
reported at the EBMT- and National Institutes of
Health-supported meeting in Florence, November 2009,13
was used as a source of consensus. Subsequently, the
guidelines were formally discussed at two successive EBMT
ADWP meetings in March and October 2010 and proposed
recommendations circulated among active members before
finalization in close interaction with the EBMT Paediatric
Diseases Working Party and the Australasian Society
for BMT.
Table 2 EBMT disease indications—(a) adults and (b) paediatrics
Disease Sibling
donor
Well-matched
unrelateda
Autologous
(a)
MS D/III GNR/III CO/II
SSc D/III GNR/III CO/II
SLE D/III GNR/III CO/II
Crohn’s GNR/III GNR/III CO/II
RA GNR/III GNR/III CO/II
Vasculitis GNR/III GNR/III CO/II
Polymyositis–
dermatomyositis
GNR/III GNR/III CO/II
CIPD GNR/III GNR/III CO/II
NMO GNR/III GNR/III CO/II
Cytopenia CO/II D/III CO/II
T1D GNR/III GNR/III D/III
RCD II GNR/III GNR/III D/III
(b)
JIA D/III GNR/III CO/II
JSSc D/III GNR/III CO/II
JSLE D/III GNR/III CO/II
Crohn’s GNR/III GNR/III CO/II
Vasculitis GNR/III GNR/III CO/II
Polymyositis–
dermatomyositis
GNR/III GNR/III CO/II
Cytopenia CO/II CO/II CO/II
T1D GNR/III GNR/III D/III
Abbreviations: CIPD¼ chronic inflammatory demyelinating polyradiculo-
neuropathy; EBMT¼European Group for Blood and Marrow Transplan-
tation; JIA¼ juvenile chronic arthritis; JSLE¼ juvenile systemic lupus
erythematosus; JSSc¼ juvenile systemic sclerosis; MS¼multiple sclerosis;
NMO¼ neuromyelitis optica; T1D¼ type 1 diabetes; RA¼ rheumatoid
arthritis; RCD II¼ refractory type II coeliac disease; SSc¼ systemic
sclerosis; SLE¼ systemic lupus erythematosus.
aA well-matched unrelated donor is defined as a 9/10 or 10/10 identical
donor based on HLA high-resolution typing for class I (HLA-A, -B, -C)
and II (HLA-DRB1, DQB1).
EBMT grades of evidence:78 I¼ evidence from at least one well-executed
randomized trial; II¼ evidence from at least one well-designed clinical trial
without randomization: cohort or case-controlled analytical studies
(preferably from more than one centre), multiple time-series studies: or
dramatic results from uncontrolled experiments; III¼ evidence from
opinions of respected authorities based on clinical experience, descriptive
studies or reports from expert committee.
EBMT grades of recommendation:78 CO¼Clinical Option: can be carried
out after careful assessment of risks and benefits; D¼developmental;
GNR¼ generally not recommended; S¼ standard: generally indicated in
suitable patients.
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General recommendations
Clinical practice
Evidence for the feasibility, efficacy and toxicity of HSCT
in various adult and paediatric ADs has been summarized
in a large number of detailed reviews and registry
analyses.14,17,18,81–87 The risks of toxicity and TRM vary
between donor source, intensity of conditioning regimens
and AD category, and the potential for safer yet equally
effective non-HSCT treatments should be actively pursued
in all cases, including modern biological therapies, where
deliverable.
Recommendations
 HSCT should be considered as a therapeutic option at
second line or beyond for patients with severe ADs
progressing despite standard established and/or ap-
proved therapy (level II).
 In patients for whom HSCT represents a treatment
option, referral should be made to a centre with
appropriate inter-disciplinary interaction using com-
bined haematological and AD specialist experience to
select and manage AD patients. Such centres should
have JACIE accreditation or equivalent (level II).
 Whenever possible, HSCT in AD should be performed in
the context of a phase II or III clinical trial with well-
defined end points and eligibility criteria in accordance
with good clinical practice and appropriate regulatory
requirements (level III).
 Approved prospective non-interventional studies may
provide meaningful clinical data where full phase III
randomized controlled trials are not feasible, and are the
preferred option over ‘ad hoc’ procedures (level III).
 If no study or clinical trial is available, the patient should
be considered under the EBMT category ‘Clinical
Option’ (CO) after documented multidisciplinary meet-
ings, clinical/research ethics committee review and/or
external expert second opinions from both HSCT and
relevant AD specialists. The alternative non-HSCT
treatment options, including potential participation in
other clinical trials, should be central to this assessment
(level III).
 In addition to JACIE accreditation (or equivalent),
centres should specifically train staff (physicians, nurses,
data managers) in specific ADs (level III).
Data reporting and biobanking
The international HSCT registries are central to the
development of HSCT to ADs. The EBMT database is
the largest worldwide and unique MED-A and specific
MED-B forms for MS, SSc, SLE, RA and CD can be
downloaded at http://www.ebmt.org/4Registry/registry3.
html. Complete data registration has proven more challen-
ging than ‘routine’, predominantly haematological, indica-
tions for HSCT since follow-up lies predominantly outside
the specialty of haematology, data managers are generally
less familiar with AD, and, in the long term, many patients
are seen in departments outside the transplant centre.
HSCT provides a unique opportunity to collect adequate
serum, plasma and cell samples in addition to biological
samples according to each AD category and organ
involvement at baseline, during the immunosuppression-
free remission, and at potential relapse for both and
pathogenetic and mechanistic studies. Local or central
biobanking, within regulatory requirements, is essential.
Recommendations
 Long-term formalized follow-up and data reporting of
all AD patients after HSCT to registries are a minimum
recommendation. EBMT MED A (or equivalent) and
disease-specific MED B (or equivalent) data reporting
are available for these purposes. Annual review and data
reporting is recommended to capture all outcomes,
including late effects of HSCT (level III).
 Centres performing HSCT for ADs should provide
systems for long-term follow-up. Annual simultaneous
follow-up consultation of the AD specialist and the
HSCT specialist is recommended. If patients are
discharged from the transplant centre for mid/long-term
follow-up under the referring specialist, the contact
details should be available to the registry (level III).
 Data managers should be adequately trained and
supervised by relevant BMT and AD specialists (level III).
 Biobanking within current regulatory frameworks allow-
ing to maximise the utility of stored biological samples
should be actively sought (level III)
Statistical aspects
The number and heterogeneity of parameters used to
measure various ADs,88–90 their rarity, the lack of standard
first-line therapy, long-term outcome data of new biological
therapies and unified definitions for remission or cure all
present challenges in the statistical evaluation of HSCT in
AD. Concepts familiar to HSCT practice, such as early
TRM, PFS and OS, are unusual to AD specialists, and
‘classical’ statistical approaches used in HSCT are less
easily applied.
Several considerations are important to designing studies
of HSCT in AD. Firstly, the definitions of the end point of
interest, especially of relapse and progression, need valida-
tion. The usual definition of PFS used to evaluate HSCT in
oncology includes both relapse and disease progression. In
ADs, these two events may be biologically and clinically
distinct, and AD-specific metrics require individual con-
sideration, with, for example, relapse in ADs not necessa-
rily resulting in progression to increased disability or death.
Secondly, in most chronic AD patients, QoL is frequently
the most important parameter and may be assessed using a
variety of generic or disease-specific instruments. Although
validated, QoL end points may be associated with a high
co-efficient of variation, even in the normal population,
and the required numbers to achieve statistical power may
be significantly increased compared with end points
conventionally used in oncology, such as PFS, OS, relapse
or death.
Randomized clinical trials (RCTs) are the best method to
reveal the effects of a therapeutic intervention and many
systematic ‘evidence-based medicine’ reviews only accept
this level of evidence. However, in HSCT in ADs,
challenges may arise in unbalanced randomization between
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treatment intensity and TRM risk, the rarity of disease or
indication, the assessment of the outcome through an
activity score, the definition of drug-free remission and the
required duration of follow-up to assess a real benefit. In
view of such ethical and practical issues, some important
clinical questions are unlikely to be adequately answered
by RCTs, and other clinical trial designs may be
more appropriate to reassure AD specialists with a view
to ultimately establishing large international trials with
adequate statistical power.
Therefore, in the context of HSCT in AD, the following
alternatives to RCTs may be considered: Prospective cohort
studies, which follow a group of patients to assess whether
events differ according to prognostic factors and therapeu-
tic options, are the best observational approach and are
more reliable than retrospective cohort studies. Case–
control studies compare a group of patients who experience
an event with another not experiencing the same event, and
examine how exposure to a suspected agent (for example,
therapeutic intervention) differs between groups. This type
of study design is useful to ascertain the cause of rare
events, although provides weaker evidence than cohort
studies.
In non-randomized studies, the major challenge is the
avoidance of bias caused by confounding factors linked
both to studied factors and to the outcome. For example,
observed differences between treatments may be linked to
the reason for choosing either treatment may result in
selection bias. The statistical method used should adjust the
comparisons for all potential prognostic factors, and the
causality between treatment and observed difference should
be discussed.
Recommendations
 Well-defined and validated parameters for each type of
AD should be used to define response progression and
remission (level III).
 In principle, randomized controlled trials are preferred,
but significant challenges should be recognized in their
application to HSCT in ADs (level III).
 Prospective non-interventional studies provide an alter-
native and pragmatic means of increasing clinical
knowledge, while eliminating bias associated with retro-
spective studies (level III).
Health economics
Despite international variation in health-care provision, all
systems have finite and constrained resources and delivery
of ‘high-cost, low-volume’ procedures, such as HSCT, is a
public health challenge. Progress in the field of HSCT in
ADs has been limited by funding not only of clinical trials,
but also of individual HSCT procedures irrespective of the
health-care provider.
Previously, standard treatments in many ADs were
relatively inexpensive. However, chronic administration of
modern biological therapies, potentially for many years,
now accumulates substantial costs. Although preliminary
health economic and QoL studies have been undertaken,
further work is necessary, particularly in conjunction with
clinical trials, to determine whether single ‘one-hit’
intensive HSCT-based treatments may prove cost-effective
by preventing, delaying or otherwise limiting the need for
biological and other treatments.91–93
Recommendations
 Economic considerations should feature early and
prospectively in the planning of clinical trials (level III).
 Studies using other sources of data (registry and
established clinical trials) should be used in evaluating
the potential cost-effectiveness of HSCT compared with
modern non-HSCT treatment options (level III).
Autologous HSCT
Mobilization of PBSCs for autologous HSCT
Autologous HSCT can be performed with either PBSC or
BM, although use of BM has been rare, and largely
restricted to the paediatric setting. In most ADs, mobiliza-
tion is safe, but G-CSF alone may induce disease flare.
Combining G-CSF with chemotherapy helps prevent flare
and improve yields of PBSC with significant decrease of T
cells in the PBSC harvest.94–98 No systematic studies
analyse the different types of mobilization chemotherapy,
but the majority of patients received priming doses of CY
of 2–4 g/m2.18
PBSCs are more easily mobilized in some AD than
others, due to previous treatments or the intrinsic nature of
some ADs. Apart from steroids, immunosuppressive, anti-
mitotic or immunomodulatory drugs should be discontin-
ued as early as clinically feasible before mobilization.
Careful cardiac evaluation is important before use of
mobilizing CY, especially in SSc and SLE, or in MS after
use of mitoxantrone: electrocardiogram, cardiac ultrasound
and, for SSc, pulmonary artery pressure, 24 h electro-
cardiogram, gating and magnetic resonance imaging (MRI)
evaluation should be evaluated in view of early reports of
potentially fatal cardiac toxicity, which decreased since the
consensus statement concerning cardiotoxicity occurring
during HSCT for ADs.99
In patients with JIA, life-threatening and fatal macro-
phage activation syndrome was reported both during
mobilization of PBSC and following engraftment of
PBSC.47,36,100 Extreme care should be exercised giving any
form of mobilization chemotherapy to severe immune
thrombocytopenia (ITP) or Evans’ syndrome patients
as these states are refractory to platelet transfusion and
fatal bleeding reported.101 In Crohn’s disease, reported
episodes of potentially life-threatening sepsis during neu-
tropenia after mobilization,102,103 and consideration should
be made to antibiotic prophylaxis and close monitoring,
with a low threshold for in-patient admission.
Recommendations
 Autologous HSC may be derived from peripheral blood
or BM. Mobilized PBSCs are preferred based on ease of
procurement and better engraftment characteristics
(level II).
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 Mobilization procedures and stem cell processing should
be performed in JACIE (or equivalent) accredited
collection centres (level III).
 Priming chemotherapy is recommended to enhance
mobilization while maintaining disease control and to
prevent potential flare, which may be a consequence of
G-CSF alone (level I).
 The recommended mobilization regimen is CY at 2–4 g/
m2 with uromixetan (Mesna) and cautious hyperhydra-
tion followed by G-CSF 5–10mg/kg (level II).
 A minimum dose of 2 106/kg CD34þ cells should be
reinfused, irrespective of any graft manipulation (level II).
 Back-up harvest is recommended, especially when graft
manipulation has been undertaken (level III).
 When CY-primed mobilization fails, a second attempt at
PBSC mobilization or BM harvest should be considered
following avoidance of immunosuppressive drugs, where
possible. Despite the lack of evidence in patients with
AD, the use of plerixafor and G-CSF may be reasonable
in poor mobilizers after weighing up the benefits and
risks. Steroid cover should be considered to reduce risk
of disease flare related to G-CSF. Cases of failure from
mobilization should be reported to the EBMT or other
registry (level III).
 Mobilization may be associated with increased risk of
mortality and morbidity in ADs:
* Caution should be exercised in SSc and SLE, where
CY priming may be associated with potentially fatal
cardiac complications (level II).
* Caution should be exercised in any patient with ITP
(primary or secondary), in whom mobilization with
CY may be associated with potentially life-threatening
bleeding events (level II).
* Caution should be exercised in patients with CD
undergoing mobilization who appear to be at in-
creased risk of severe infection. Consideration should
be made for antibiotic prophylaxis and increased
monitoring or in-patient admission (level III).
Conditioning regimens for autologous HSCT
The original guidelines proposed that centres restricted
their initial studies to one of four ‘standard’ HSCT
regimens used in haemato-oncology and aplastic anaemia:
Although TBI had been the focus of many animal studies
and had potential advantages, excess toxicity was acknowl-
edged to be an issue.104 In the EBMT registry analyses,
most patients had received high-dose CY-based regimens,
mainly directed against rheumatological conditions (SSc,
RA, SLE). The most commonly used regimen was the
‘BEAM’ regimen (BCNU 300mg/m2 on day 6, Ara-C
200mg/m2 and etoposide 200mg/m2 on day 5 to 2,
melphalan 140mg/m2 day 1), principally for MS, where it
was frequently combined with anti-T globulin (ATG). Use
of TBI was relatively rare (6%), but featured significantly
in the treatment of JIA (45%).
Conditioning regimens were divided retrospectively into
(a) ‘high intensity’, including TBI or high-dose busulphan-
containing regimens, (b) ‘low intensity’, referring to CY
alone, melphalan alone and fludarabine-based regimens, or
(c) ‘intermediate intensity’, including other combinations,
such as BEAM, and, in most patients, the combined use of
ATG with high-dose CY or other chemotherapy. There was
a significant relationship between efficacy and intensity,
balanced by the inverse relationship with toxicity as
reflected by TRM. Overall, ‘intermediate intensity’ con-
ditioning regimens were associated with significantly
improved outcomes compared with ‘low-’ and ‘high-’
intensity regimens.17,18
Although more profound responses are possible with
high-intensity regimens, caution should be exercised given
the substantial short- and long-term toxicity. A further
analysis of the MS data supports the significantly higher
TRM with oral high-dose busulphan.52 The use of irradia-
tion-containing protocols outside of clinical trials has been
questioned owing to the long-term adverse effects, including
malignancies, even after low-dose irradiation.14,82,105–110
Allergic reactions to ATG and other serotherapy may be
prevented with intermediate-dose corticosteroids. This may
be especially important in patients with MS where fever can
worsen neurological symptoms.25,111
Recommendations
 Given the relatively high risk of TRM and late effects of
‘high-intensity’ conditioning regimens (including irradia-
tion at any dose), their use should be restricted to clinical
trial setting (level III).
 If a patient is being treated under the EBMT CO
category (Tables 2a and b), the following intermediate
intensity conditioning regimens provide a balance
between safety and efficacy, while facilitating data
analysis and clinical trial planning (level II):
* CY 200mg/kg with polyclonal or monoclonal anti-T-
cell serotherapy is recommended generally; with CY
120mg/kg, fludarabine 150mg/kg and ATG (or other
anti-T-cell serotherapy) as an alternative in paedia-
trics.
* For MS specifically BEAMþATG (or other anti-T-
cell serotherapy) is recommended.
* Choice of anti-T-cell serotherapy will depend on
availability, but may include polyclonal ATG (for
example, thymoglobulin, Fresenius and lymphoglobu-
lin type) and MoAbs (for example, alemtuzumab).
Consideration should be given to the short- and long-
term toxicities of the various types of serotherapy
(level II).
Graft manipulation in autologous HSCT
Lymphocyte depletion of autologous PBSC was originally
recommended and its use has been widespread, particularly
in the form of CD34þ selection.18 Despite the availability
of various clinical grade separation devices for graft
manipulation, and theoretical concepts supporting the use
of T- or B-cell depletion, none of the EBMT registry
outcome analyses to date support ex vivo depletion
strategies. A randomized controlled pilot trial in 30 severe
RA using ‘low-intensity’ conditioning with CY 200mg/kg
showed no benefit for CD34þ selection.34 In addition, the
selection procedure adds significantly to the cost of an
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autologous procedure and potentially requires additional
numbers of CD34þ cells to be harvested. Given that
pathogenetic mechanisms vary between ADs, a tailored
approach to graft manipulation within clinical trials may
ultimately be appropriate, but for the present there is little
to support the routine use of graft manipulation.
Recommendations
 There is no evidence to support ex-vivo graft manipula-
tion, although decisions can be made on an individual
patient basis (level II).
 Ex-vivo graft manipulation should be the focus of clinical
trials (level III).
General status for autologous HSCT, infection prophylaxis
and supportive care
Patients with ADs often have significantly reduced
immunity related to chronic immunosuppressive treatments
and intrinsic immune suppression in some diseases, such as
SLE and T1D. The profoundly immunosuppressive nature
of the conditioning regimens (use of ATG or other anti-T-
cell serotherapy), and ex-vivo graft manipulation of the
autologous harvest, are associated with increased risk of
acquired and re-activated infections. Instances of infections
more commonly associated with allogeneic HSCT, includ-
ing EBV post transplant lymphoproliferative disorder and
CMV disease, have been reported.52,112,113 In addition,
there are also reports of fever being associated with
neurological deterioration in patients with MS,25,111 and
engraftment syndrome has been recognized as an potential
issue in patients with ADs.114,115
The risks of TRM and other serious complications
should be minimized by patient selection and by minimiz-
ing infective and other risks with prophylactic, pre-emptive
and other supportive care strategies. Facilities for treating
patients with AD with autologous HSCT should be broadly
similar to those available for allogeneic HSCT practice.
Although induction of infertility is not universal,32,116 the
effect of HSCT on gonadal function is also an important
aspect of the pre-HSCT counselling. Although EBMT
registry analyses17,18 have shown that PFS improves in
younger age groups (o35 years), there is no evidence upon
which to base an upper age limit.
Recommendations
(a) Exclusion criteria for SCT
(i) Organ dysfunction
 Pre-HSCT evaluation of heart, lung, kidney and
gastrointestinal function appropriate to the AD is
critically important. Patients with advanced cardiac
disease (left ventricular ejection fractiono50% in SSc,
o40% in other indications, uncontrolled ventricular
arrhythmias, pericardial effusions 41 cm), renal in-
sufficiency (creatinine clearance o40mL/min per m2
in SSc or o30mL/min per m2 in other indications),
respiratory disease (diffusing capacity of the lung for
carbon monoxide o40% predicted, mean pulmonary
artery pressure 450mmHg in SSc or clinical/sub-
clinical ventilatory impairment due to respiratory
muscle involvement in MS) or active gastrointestinal
bleeding should be excluded (level II).
(ii) Uncontrolled infection
 Any uncontrolled acute or chronic infection, including
HIV, human T-lymphotropic virus type 1 and 2,
hepatitis B surface antigen positivity and hepatitis C
PCR positivity, should be considered as a contra-
indication (level II).
(iii) Pregnancy
 Pregnancy should always be excluded within 7 days of
administering mobilization chemotherapy or HSCT
with a blood based b-human chorionic gonadotrophin
assay (level III).
(b) Infections
(i) Diagnostic procedures
Pre-transplant testing
 Pre-transplant workup should include screening
for CMV, HSV, VZV, EBV, HIV, human T-lympho-
tropic virus type 1 and 2, hepatitis viruses
and toxoplasmosis in all patients, with other infection
screening appropriate for geographical location
(level II).
During hospitalization for the HSCT procedure
 CMV Ab-positive patients receiving ATG or other
serotherapy, or receiving manipulated autografts, are
recommended to undergo CMV PCR or antigenaemia
screening for the first 100 days post transplant
(level III).
 EBV Ab-positive patients receiving ATG or other
serotherapy, or receiving manipulated autografts, are
recommended to undergo EBV PCR screening for the
first 100 days post transplant, with active surveillance
for post transplant lymphoproliferative disease ac-
cording to local practice (level III).
(ii) Infection prophylaxis
In-patient accommodation for HSCT period
 All patients should be accommodated in isolation
facilities, with appropriate clean air facilities (for
example, laminar flow or HEPA) in accordance with
JACIE accreditation standards during BM aplasia/
severe neutropenia (level II).
Bacterial, fungal and viral prophylaxis
 All patients should receive broad-spectrum anti-
bacterial prophylaxis during aplasia (for example,
quinolones), anti-fungal prophylaxis (for example,
azoles) and herpes prophylaxis (aciclovir) during and
for at least 100 days post transplant (level II).
 All patients who are negative for anti-CMV antibodies
should receive CMV-negative blood products (level II).
 All patients should receive prophylaxis against Pneu-
mocystis jiroveci (for example, oral co-trimoxazole
(TMP/SMX) 3 times weekly as tolerated or, if not
tolerated, alternatives, such as nebulized pentamidine,
dapsone or atovaquone) for at least 100 days post
transplant (level III).
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 All patients positive for anti-toxoplasma antibodies
should receive oral co-trimoxazole (TMP/SMX) daily
until day –1, then after reconstitution of blood counts
3 times weekly for at least 100 days post transplant, as
tolerated, as per Pneumocystis jiroveci (level II).
 Consideration should be made to risk of reactivation
of tuberculosis, with prophylaxis through the period of
immune suppression where appropriate (level II).
 I.v. Ig replacement may be considered in carefully
selected cases after weighing up the benefits, risks and
costs of administration (level III).
(iii) Pre-emptive therapy
 CMV reactivation (diagnosed by PCR or Ag) should
be treated with ganciclovir, valganciclovir or foscarnet
according to centre policy and protocols (level II).
(iv) Therapy of fever and proven infections
 Treatment of fever and established infection should
follow centre policy and protocols (level III).
 Administration of ATG or other serotherapy should
be accompanied by an intermediate dose of corticos-
teroids. Fever and other reactions, which may result in
neurological deterioration in patients with MS, should
be promptly treated according to centre policy and
protocols (level III).
 When a patient presents a new, high and well-tolerated
fever at the time of neutrophil recovery, engraftment
syndrome should be considered along with infective
causes (level III).
(c) Supportive care
(i) Prophylaxis of haemorrhagic cystitis
 Patients receiving high doses of CY should receive
uromixetan (Mesna) and cautious hyperhydration
(level I).
(ii) Transfusion
 Platelet and erythrocyte transfusions should be ad-
ministered according to centre policy and protocols.
Blood products should be irradiated.
(iii) Fertility, pregnancy and menopause
 Before mobilization and HSCT, consideration should
be given to chemotherapy-induced infertility (semen,
oocyte or embryo cryopreservation as appropriate)
risk of induction of premature menopause, and
ultimate need for hormone replacement therapy,
where appropriate. Pregnancy should be excluded
within 7 days of administering mobilization or
conditioning chemotherapy (level III).
(d) Follow-up after HSCT and ongoing responsibility for the
patient
 All patients should remain under the direct routine
care of the transplant specialist for at least 100 days
post transplant, or longer, if necessary until clinically
stable. Thereafter, combined care between transplant
specialist and referring organ/AD specialist with
joint annual review as a minimum is recommended
(level III).
Principal indications for autologous HSCT
This section will cover the background and considerations
for the main current indications for autologous HSCT,
where large-scale multicentre clinical studies are active or
are potentially feasible for a proportion of patients.
Patients who are unfit for HSCT should be excluded.
Multiple sclerosis. MS is the most frequent chronic
inflammatory demyelinating disease, with a prevalence of
1 in 700 adults, believed to be mediated by autoreactive
lymphocytes that invade the central nervous system causing
damage to oligodendrocytes and axons and resulting in
demyelination, neuronal death and brain atrophy.117 In the
most frequent type, the disease is initially characterized by
relapses and remissions due to repeated inflammatory
attacks in the central nervous system, as demonstrated by
the appearance of new T2-weighted- or contrast-enhancing
lesions on MRI studies and characterized pathologically by
inflammatory infiltrates rich in T cells, macrophages/DCs,
and, in certain subforms, also in antibodies and comple-
ment (relapsing–remitting phase). The second phase is
associated with slow progression of disability, with a
progressive decline in inflammation (secondary progressive
phase), characterized by microglial activation, but pre-
dominantly by axonal/neuronal loss. Some patients follow
a progressive course from the onset (primary progressive
form). The Extended Disability Scoring Scale is the most
commonly used means of assessing function and progres-
sion in MS.88
First-line treatments are the immunomodulators, such as
glatiramer-acetate118 and b-IFN,119 which delay progres-
sion of disability. Very recently, the orally available
sphingosine 1 phosphate receptor agonist, fingolimod,
which is considerably more effective than b-IFN and
glatiramer-acetate,120 has also been approved as first-line
therapy. Second-line treatments are mitoxantrone121 and
the MoAb, natalizumab.122 Both first- and second-line
treatments alter the natural course of disease by targeting
the early phase of inflammation, but virtually all failed to
halt the build-up of disability when used in the later
secondary progressive phase of disease. The administration
of such agents is complicated by infrequent, but sometimes
serious, adverse events, such as progressive multifocal
leukoencephalopathy with natalizumab, serious infections
and other adverse events with fingolimod, and cardiomyo-
pathy and secondary leukaemia with mitoxantrone treat-
ment.123 On the horizon are other agents, all aimed at the
early inflammatory phase (for example, cladribrine, alem-
tuzumab, teriflunomide, laquinimod, fumaric acid, ocreli-
zumab and daclizumab), but those tested in a small
population of SPMS (cladribine and alemtuzumab) failed
to show effectiveness. Overall, a subset of non-responders
has been described in clinical trials with both old and new
therapies, associated with the need to maintain long-term
immunosuppression.
Since 1996,19 HSCT has been extensively reported
worldwide as a tool for inducing a prolonged restoration
of self-tolerance in MS patients progressing despite on-
going, conventional treatments year.23,25,26,124–128 The
Autologous Stem cell Transplantation International MS
Trial is a multicentre prospective randomized phase II
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study with a primary MRI end point. Despite a low
accrual, 21 patients were included and are now followed up
by clinical and MRI assessment. ASTIMS was stopped
owing to enrolment difficulties, but a prospective phase III
trial comparing autologous HSCT vs best approved/
available therapy is currently under consideration between
European and North American experts.12,129 Most of the
patients worldwide have been conditioned with
BEAMþATG schedule showing satisfactory toxicity/
efficacy equipoise.52 CY and ATG conditioning was used
for autologous HSCT in 21 early relapsing–remitting
patients with low (but not negligible) toxicity. After a
range 24–48 months follow-up, patients had no deteriora-
tion in the Extended Disability Scoring Scale score, 16/21
were free of relapses and significant improvements in
neurological disability were reported.27 A larger experience
is needed to assess the role of lower intensity regimens and
a randomized trial is ongoing (http://www.clinicaltrials.
gov). A better outcome in relapsing–remitting over
secondary progressive forms, including sustained improve-
ment of the disability, has been recently reported in single
centre experiences.126,130
Recommendations
 In MS, the ideal target patients for autologous HSCT are
in the relapsing–remitting phase, showing high inflam-
matory activity, both clinically and by MRI (Gdþ
contrast-enhancing lesions and/or new T2 lesions in two
subsequent scans), who are rapidly deteriorating despite
the use of one or more lines of approved treatments
(level II).
 Patients with ‘malignant’ (Marburg type) MS, who
develop severe disability in the previous year, are also
suitable candidates for autologous HSCT (level II).
 Secondary progressive MS patients should be considered
for autologous HSCT only when some inflammatory
activity is still evident, that is, either clinical relapses or
Gd-enhancing lesions, and/or new T2 MRI lesions on
two subsequent scans, and who have shown a sustained
and clinically relevant increase in disability in the
previous year (level II).
 Patients who have lost the ability to walk (usually an
Extended Disability Scoring Scale upper limit of 6.5)
must be excluded, except for ‘malignant’ forms (Marburg
type) (level II).
Systemic sclerosis. SSc is a rare AD of unknown origin,
with an incidence of 1 in 100 000 characterized by skin and
visceral (lung, gastrointestinal, cardiovascular and renal)
fibrosis secondary to excessive collagen deposition.131
Limited and diffuse cutaneous (dcSSc) forms can be
distinguished by the extent of skin and organ involvement
and auto-Ab profile.132,133 Rapidly progressing dcSSc
within the first 4 years after disease onset, observed in
10–20% of cases, is life-threatening disease with 3–5 years
survival between 50 and 80%.134–136 Presence of extensive
skin thickening (as measured by the Rodnan modified skin
score), renal (proteinuria) or lung involvement (as demon-
strated by pulmonary functions tests or on CT scan) and
high age at onset are important risk factors.135–137 SSc
patients only marginally benefit from prolonged oral CY,
the only treatment with some proven efficacy.138,139
HSCT registry data, case reports and pilot studies in
Europe45,48,140 and the United States of America22,28 in dcSSc
consistently showed rapid and sustained clinically relevant
improvement of functional ability and skin thickening (in the
majority of patients, stabilization of organ function (heart,
lung, kidney)), but at the expense of toxicity and early
TRM45 in the initial studies. Patient eligibility has been
broadly similar in different studies, that is, targeting early
dcSSc with a Rodnan modified skin score above 15 and some
degree of internal organ involvement (mainly lung) or with
rapidly progressing skin fibrosis in the first 2 years after AD
onset. Different HSCT regimens have been employed, but
most included high doses of CY for mobilization (4 g/m2)
and conditioning (200mg/kg total dose with ATG). Com-
parison with ‘historical controls’, including those from recent
randomized trials of CY vs placebo, suggests that auto-
logous HSCT induces more robust and sustained responses
of skin involvement and functional status.48,29–31,71,110 The
benefits need to be weighed against the risks of TRM, which
appears to be decreasing with increasing experience and
better patient selection,18,99 although definitive statements
regarding relative safety and efficacy need to await the final
analysis of randomized trials.
Two prospective, randomized controlled trials, the
multicentre EBMT sponsored ASTIS trial conducted under
the auspices of EBMT and European League against
Rheumatism in Europe and the single centre ASSIST204
study, run by the Chicago group, recently completed
recruitment and results are expected by the end of 2011.
The SCOT trial in North America is still accruing. ASTIS
and SCOT are large multicentre RCTs with similar
eligibility criteria and comparable outcome measures and
include control treatment with 12 monthly i.v. pulses CY,
but differ in the conditioning regimen being without
(ASTIS) or with (SCOT) irradiation, allowing future
comparison between intense immunosuppression vs mye-
loablation. Long-term follow-up of patients in all of these
trials is essential to examine possible divergence of survival
and to study late effects of treatment.
Although the outcome of juvenile systemic sclerosis is
better than the adult form, extensive skin and pulmonary
involvement show a 5-year mortality of 10%.141 As with the
adult form, immunosuppressive drug strategies may be
used, but there is no satisfactory treatment. Autologous
HSCT in juvenile systemic sclerosis has been explored in
five patients (median age 12 years) incorporated in a larger
analysis of SSc. The patients with severe lung disease were
treated with CY-based conditioning (120–200mg/kg) and
selected autograft. After a median follow-up of 37 (range
13–67) months, all five children were alive and three of
them are in complete and sustained remission.48,54
No published data are available to make recommenda-
tions for limited SSc patients in any age group.
Recommendations
 Autologous HSCT can be considered as treatment for
selected patients with early dcSSc and juvenile systemic
sclerosis (Tables 2a and b) (level II).
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 Patients to be considered for HSCT include those with
diffuse SSc with disease duration p5 years since
development of first non-Raynaud’s symptoms with a
modified Rodnan skin score X15 plus major organ
involvement (with documented evidence of onset or
clinically significant worsening in the previous 6 months)
as defined by at least one of:
(a) respiratory involvement with a DLCO and/or forced
vital capacity p70% of predicted and evidence of
interstitial lung disease (chest X-ray and/or HR-CT
scan) (level II)
(b) cardiac involvement with conduction disturbances,
including second-/third-degree atrioventricular block,
intra-ventricular conduction disturbance, left axis
deviation, atrial or ventricular rhythm disturbance,
pericarditis as defined by p1 cm on cardiac ultrasound
(level II)
(c) renal involvement with proteinuria 40.3 g/24h, not
explained by other causes than systemic sclerosis (level II).
Systemic lupus erythematosus. SLE is a heterogeneous
chronic AD with a prevalence of 40–50 per 100 000,
predominantly females (485%) with higher frequency
among people of African origin.142–144 The outcome of
active severe SLE due to kidney, lung, heart or brain
involvement has improved in adults and children with early
diagnosis and new immunosuppressive agents combined
with overall tighter control of blood pressure and
infections.145 First-line therapies aimed at inducing remis-
sion within the first 6–9 months of disease flare include
corticosteroids in combination with mycophenolate mofetil
or CY using the classical National Institutes of Health
regimen146,147 or the Eurolupus regimen,148 with lower CY
doses for shorter duration and same efficacy. Among other
drugs tested for induction, the use of various MoAbs
against T- or B-cell receptors or adhesion molecules all
failed to demonstrate their superiority when tested in phase
III trials, except for belimumab, an MoAb against B-
lymphocyte stimulator soluble receptor.149
Response rates to standard therapy vary according to the
criteria, extent of visceral involvement, ethnic origin and
socio-economic profile. Approximately 20% (10–36%) of
active SLE patients fail to respond; 50% (10–65%) relapse
after initial treatment, 5–15% evolve towards end-stage
disease and 10–15% die at 10 years.150,151 Initial and
persistent renal, cerebral or severe pulmonary involvement
along with overall disease activity are important predictors
of poor long-term survival.151,152
Among 200 autologous HSCT worldwide for SLE, the
largest experience comes from retrospective EBMT ADWP
registry (n¼ 53),49 and from the Northwestern University
prospective single centre study (n¼ 50)153 with a 50%
probability of 5-year disease-free survival in both studies.
In addition to a decrease in the overall disease activity and
serological responses, autologous HSCT reversed pulmon-
ary dysfunction and anti-phospholipid syndrome with
durable treatment-free responses lasting 5 or more years
on minimal or no treatment. In terms of safety, the
Northwestern University study reported TRM of 4% (2/50,
including one death from fungal infection during mobiliza-
tion),153 whereas the first multicentre EBMT analysis
showed a more substantial TRM of 12% in early published
cohort of 54 patients analyzed up to 2002,49 subsequently
decreasing by around half in a later cohort of 28 patients
transplanted from 2002 to 2008 (D Jayne, personal
communication). In the EBMT registry analysis, severe or
fatal infections tend to be more frequent among the 85 SLE
patients with autologous HSCT as compared with other
groups of patients (39% vs 22%).18 In addition, prelimin-
ary analysis of 18 paediatric SLE patients in the EBMT
database, with 41 months median follow-up after auto-
logous HSCT, confirmed that nine patients are in CR,
while seven relapsed and two died of TRM (M Rabusin,
personal communication). An updated analysis of the 85
patients reported to the EBMT is in preparation (D Jayne,
personal communication).
In summary, in patients with severe SLE refractory to
conventional immunosuppressive therapies, autologous
HSCT can achieve sustained clinical remissions with
qualitative immunological changes153,154 not seen with
other forms of therapy despite significant TRM. Overall
prospective and retrospective data highlight the need for
careful patient selection, as well as recognition of the
intrinsic immune suppression and other risks associated
with advanced SLE. Ideally, the role of autologous HSCT
in the treatment of severe SLE in both adults and children
should be established in adequately powered RCTs. Until
larger international RCTs are available, smaller phase II
studies and stronger registry analyses should be pursued to
help define a core set of clinical data biological sample
collection to be collected in every study.
Recommendations
 Current uncontrolled data suggest that autologous
HSCT can be considered as treatment for carefully
selected subpopulations of SLE patients early in their
disease course, with reliably predicting poor prognostic
factors, according to combinations of demographic,
clinical and laboratory markers (Tables 2a and b)
(level II).
 Patients to be considered for HSCT would reasonably
include those with sustained or relapsed active BILAG
category A SLE remaining steroid dependent after at
least 6 months of the best standard therapy, using
mycophenolate mofetil or CY with or without anti-
CD20 and other MoAbs, with documented evidence of
visceral involvement or refractory SLE as defined by at
least one of:
(a) Kidney involvement: meeting the criteria for BILAG
category A with a renal biopsy of less than 12 months
showing evidence of World Health Organization class
III or IV glomerulonephritis (level II).
(b) Any other type of vital organ involvement with BILAG
neurological category A, cardiovascular or pulmonary
category A, vasculitis category A and autoimmune
cytopenias category A (level II).
(c) Associated anti-phospholipid syndrome with recurrent
thromboembolism despite maximal anticoagulation
(level III).
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Crohn’s disease. CD is an inflammatory bowel disease
affecting both adults and children characterized by a
chronic clinical course, with exacerbations and remissions,
and by a trans-mural inflammation that may affect
different segments of the digestive tract. In developed
countries, prevalence of CD is around 0.1%. Recent genetic
discoveries have underlined the role of innate and adaptive
immunity, as well as epithelial function. Nevertheless, the
pathogenesis of CD and the role of environmental factors
remain unclear. Current pharmacological treatments based
on corticosteroids, immunosuppressants (for example,
thiopurines and MTX) and biological therapies (particu-
larly anti-tumour necrosis factor drugs) are used early in
the course of the disease.
Despite the major recent progress in the treatment of
CD, some patients fail all available therapies, including
immunosuppressants and biological therapies. There is a
subset of patients in whom the disease runs an aggressive
course with progressive tissue damage and potentially
reduced life expectancy.155–158 Surgery may be considered
as an option in many cases, but may lead to short bowel
syndrome or to a definitive stoma, which may be refused by
the patient.
Beyond case reports and short series, autologous HSCT
as primary treatment for CD has been investigated in several
phase II studies, one with extended follow-up.38–40,102 The
majority of patients have been adult, although paediatric
patients have also been treated (Table 1). Responses have
been encouraging and prolonged, but the progressive
incidence of relapse with long-term follow-up raises ques-
tions regarding the benefits over conventional treatments
and also in relation to salvage and maintenance treatments
post-HSCT.159
ASTIC is a multicentre, prospective, randomized phase
III study for adult patients with CD supported by
European Crohn’s and Colitis Organization and sponsored
by EBMT comparing the relative benefits of autologous
HSCT with best available medical therapy. In addition,
paediatric specialists have proposed the following consen-
sus criteria for refractory disease (a) corticosteroid-resistant
disease, with no response to equivalent prednisolone dose
of 1mg/kg daily (max 60mg daily) for 8 consecutive weeks,
or corticosteroid dependence or relapse within 3 months of
stopping treatment and (b) lack of response to, or
intolerance of, at least one of; azathioprine or mercapto-
purine for 4 consecutive months, MTX for 3 consecutive
months, infliximab (5mg/kg) given as 0, þ 2 and þ 6 weeks
regimen infusions, or thalidomide 2mg/kg for 8 consecutive
weeks.54
Recommendations
 In the absence of results from large studies, autologous
HSCT should be reserved for patients with severe CD
unresponsive to multiple lines of therapy, including
immunosuppressive agents and anti-tumour necrosis
factor MoAbs (Tables 2a and b) (level II).
 HSCT may be considered for patients with active CD
refractory to immunosuppressants and biologics. The
disease activity has to be proven by morphological
evaluation (endoscopy, CT scan). Other therapeutic
options, including surgery, should be discussed case by
case, whenever acceptable. Autologous HSCT may be
considered for the following situations (level III):
* Active disease, uncontrolled by medical therapies.
* Extensive disease in which surgical resection would
expose the patient to the risk of small bowel
syndrome.
* Refractory colonic disease and perianal lesions where
coloprotectomy with a definitive stoma not accepted
by the patient.
 Paediatric CD requires special consideration and appro-
priate expertise in patient selection (level III).
Orphan diseases and rare indications for autologous HSCT
In other ADs, the strength of established competing
therapies and the limited evidence base have made HSCT
a rare consideration. Rare cases of resistant disease may be
considered in a multidisciplinary setting within the ‘CO’
category. Enrolment onto a clinical trial should be pursued,
if feasible. Full data reporting to EBMT or equivalent
registry is mandatory, and will facilitate prospective non-
interventional studies in these indications.
Autoimmune cytopenias. The majority of patients with
immune cytopenia respond well to treatment, and many
require no intervention, but occasionally necessitate high
levels of immunosuppression and supportive care with life-
threatening situations. ITP is the most common auto-
immune cytopenia, with an incidence of the chronic form of
5.8–6.6 per 100 000 in adults and 0.46 per 100 000 in
children. ITP in children follows a chronic course in 25% of
patients, and 10% require chronic immunosuppressive
therapy.160,161 Autoimmune haemolytic anaemia (AIHA)
is less frequent with an incidence of 2.6/100 000.162
Paediatric AIHA follows a chronic course in 20% of
patients between 2 and 12 years, with a reported mortality
rate of 10%.163 Evans’ syndrome and thrombotic throm-
bocytopenic purpura are rarer, but more frequently
associated with life-threatening complications with a
mortality rate in children up to 30%.163
Among 52 patients with ITP, AIHA and Evans’ syndrome
in the EBMT registry, who underwent autologous or
allogeneic HSCT up to 2008 in 50 centres, OS at 5 years
was 61±5%. Analysis of the 24 children with immune
cytopenias (19 allogeneic HSCT and 7 autologous HSCT)
confirmed a 60% PFS with allogeneic HSCT vs 35% with
autologous HSCT, with a TRM of 20% overall.54,164 It
remains unclear whether symptomatic ‘cytopenia-free survival’
is best achieved with autologous or allogeneic HSCT,51,161,165
but, given the low number of HSCT per centre, it is unlikely
that a prospective study can ever be successfully completed.
Some patients have clearly benefited and harmonizing
procedures may yield more interpretable data in the future
through prospective non-interventional protocols.
Recommendations
 HSCT may be considered for patients with ITP, AIHA
and Evans’ syndrome refractory to at least two lines of
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treatment (including rituximab and TPO receptor
agonists for ITP) under the ‘CO’ criterion (Tables 2a
and b) (level II).
 For adults under 50 years, autologous HSCT should be
considered if no HLA-matched sibling donor is available
and is preferred over alternative donor HSCT (level II).
 For paediatric patients, autologous HSCT is an option in
patients with autoimmune cytopenia, where no fully
HLA-compatible sibling or unrelated donor can be
identified, or in patients with Evans’ syndrome with no
9/10 HLA-matched unrelated donor (level II).
Juvenile idiopathic arthritis. JIA is the most common
rheumatic disease in children and a major cause of
disability. In 5–10% of children with the systemic and
polyarticular onset forms, the disease is refractory to non-
steroidal anti-inflammatory drugs and immunosuppressive
drugs such as MTX and corticosteroid with an estimated
mortality in the whole group of 2–4%. The introduction of
biological agents, such as anti-tumour necrosis factor and
anti-IL-1 and -6 receptor agents, had a major impact on
outcome of children with the polyarticular form, but is less
effective in active systemic disease.166,167
A retrospective European analysis included 34 JIA
patients undergoing autologous HSCT using ATG, and
CY±low-dose TBI (4Gy) and T-cell depletion.47 Over half
the patients achieved a complete drug-free remission, while
another six patients (18%) showed a partial response. The
incidence of complications was high with three episodes of
fatal haemophagocytic (macrophage activation) syndrome
and TRM of 9%. Long-term remission has been confirmed
in the majority of patients.47,36,100,37
Recommendations
 HSCT can be considered as treatment for carefully
selected subpopulations of patients with JIA who meet
the following inclusion criteria under the ‘CO’ criterion
(Table 2b):
* systemic onset with polyarticular course or polyarti-
cular onset,
* corticosteroid-resistant disease defined as no response
to equivalent prednisone dose of 2mg/kg per day (max
60mg daily) for 8 consecutive weeks,
* inadequate response to, or intolerance to, at least two
disease-modifying antirheumatic drugs, including bio-
logical agents such as etanercept, infliximab, adalimu-
mab, anti-IL-1 receptor and anti-IL-6 receptor agents,
and
* unacceptable toxicity from disease-modifying anti-
rheumatic drugs or corticosteroid therapy (level II).
 Patients with a history of previous macrophage-activating
syndrome or recent systemic disease flare should receive
ciclosporin together with maintenance prednisone during the
conditioning regimen phase before the transplant (level II).
Rheumatoid arthritis. Before the widespread introduction
of biological therapy, severe RA was the most common
indication for autologous HSCT. The procedure was well
tolerated and produced good initial responses, but early
relapses were observed necessitating re-introduction of
anti-rheumatic treatments. Seronegative disease was more
responsive with some prolonged remissions. The EBMT
supported the phase III ASTIRA trial to address the role of
post transplant maintenance, but, in the midst of emerging
biological therapy, it recruited poorly and was closed.
Sporadic patients continue to be reported to the registry,
but the place of HSCT is unclear.50,34,168–170 Exceptional
patients may be considered on a ‘CO’ basis, and data
registration is a minimum recommendation (Table 2a).
Systemic vasculitis. The systemic vasculitides are hetero-
geneous collection of diseases, including Behc¸et’s disease,
Wegener’s granulomatosis, cryoglobulinaemia, Churg–
Strauss angiitis, polychondritis, Takayasu arteritis, poly-
arteritis nodosa and undifferentiated vasculitis, occasion-
ally life-threatening. A retrospective registry-based analysis
summarized 14 patients with active, resistant disease who
received a first autologous HSCT for various forms of
vasculitis. Responses were seen, with half of the patients
being complete responders,53 in the various subtypes of
vasculitis with autologous HSCT.171–175 Despite limited
evidence, autologous HSCT may be considered on a ‘CO’
basis in patients with systemic vasculitis after failure of at
least two lines of conventional treatment with data
registration a minimum recommendation (Tables 2a and b).
Dermatomyositis and polymyositis. Among the eight cases
of polymyositis and dermatomyositis registered in the
EBMT database, there are some encouraging anecdotal
responses, especially in children, but others in adults are
disappointing.176–179 No definitive recommendations can be
made other than that exceptional patients may be con-
sidered on a ‘CO’ basis, and data registration is a minimum
recommendation (Tables 2a and b).
Chronic demyelinating inflammatory polyneuropathy and
neuromyelitis optica. Chronic demyelinating inflamma-
tory polyneuropathy may be chronically disabling and
resistant to treatment. In such cases, autologous HSCT has
resulted in improvement or stabilization of neurological
status and cessation of immunosuppression.180–182 Achiev-
ing an accurate diagnosis of chronic demyelinating
inflammatory polyneuropathy as per the European Federa-
tion of Neurological Societies guidelines with an active
inflammatory component is mandatory.183
Among the limited published and EBMT registry data
for HSCT in neuromyelitis optica registered in the EBMT
database, anecdotal responses of neuromyelitis optica to
HSCT were encouraging, although relapse may not be
prevented.184,185
The very limited evidence of autologous HSCT in both
chronic demyelinating inflammatory polyneuropathy and
neuromyelitis optica make any robust clinical recommen-
dations difficult, but given some favorable reported out-
comes, treatment-resistant cases may reasonably be
considered on a ‘CO’ basis involving both experienced
neurologists and haematologists.
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Recommendations
 Patients with orphan diseases or rare indications may be
considered for treatment as a ‘CO’ (Tables 2a and b),
although enrolment onto a prospective clinical trial or
prospective non-interventional study is highly recom-
mended, whenever possible (level III).
 Long-term formalised follow-up of all patients using
HSCT registries (for example, EBMT MED-A/B report-
ing) is a minimum recommendation (level II).
Evolving indications for autologous HSCT
Type 1 diabetes mellitus. T1D results from a cell-mediated
autoimmune attack against pancreatic b-cells. The incidence
of T1D in children in Europe varies between 5 and 40 per
100 000 new cases per year. Patients with T1D depend on
exogenous insulin administration for survival and the best
established treatment is tight control of blood sugar
accomplished by either frequent daily injections or con-
tinuous s.c. infusion of insulin, that is, intensive insulin
therapy, which reduces the risk of retinopathy, nephropathy
and neuropathy by 35–90% when compared to conven-
tional therapy with 1–2 insulin injections per day.186,187
Autologous HSCT has been explored among other
immunotherapeutic approaches aiming at re-inducing
tolerance at the time of early onset of T1D and encouraging
persistence of b-cell function, which improves outcomes.188
In Brazil, 20 patients with new onset T1D presenting
without ketoacidosis or steroid exposure were treated with
autologous HSCT without TRM, 12 patients experiencing
sustained insulin independence, normal HbA1C and
increased C-peptide levels.41,42,189 In the EBMT database,
10 T1D cases are registered with initial outcomes reflecting
similar feasibility and safety of autologous HSCT.43
Refractory type II coeliac disease. Coeliac disease affects
around 0.5–1% of the population, the vast majority of
patients being succesfully managed with a gluten-free diet,190
but a small proportion of patients (2–5%) are refractory.
Immunophenotyping of intraepithelial lymphocytes in the
small bowel can differentiate refractory type II coeliac
disease patients with aberrant phenotype, lacking surface
expression of CD3 and CD8, at high risk of developing
enteropathy-associated T-cell lymphoma. Based on the poor
prognosis of enteropathy-associated T-cell lymphoma, 18
patients with refractory type II coeliac disease resistant to
cladribine were identified, and 13 underwent melphalan-
based conditioning and autologous HSCT, resulting in
improvement in clinical and laboratory parameters, despite
one patient suffering TRM and one patient developing
enteropathy-associated T-cell lymphoma after 4 years.
Improvement in prognosis was supported by mortality from
enteropathy-associated T-cell lymphoma in the five patients
who did not receive autologous HSCT.191,192
Recommendation
 T1D and coeliac disease are relatively common ADs, but
the role of autologous HSCT remains unclear. Patients
should only be treated on an IRB/REC-approved
prospective clinical trials (level III).
Allogeneic and syngeneic HSCT
Allogeneic HSCT has rarely been used in the treatment of
AD, and syngeneic HSCT, even more rarely. Whereas
syngeneic HSCT offers as means of lymphohaemopoietic
replacement with risks to the patient no greater than
autologous HSCT and potential greater benefit in
some,193–195 various forms of allogeneic HSCT are asso-
ciated with toxicity and TRM risks, which far outweigh the
risks of most patients with severe ADs. The area where
allogeneic HSCT has mostly been used has been in the
context of immune cytopenia, predominantly in the paedia-
tric setting where unrelated and cord blood procedures are
reported.44,51,196 Donor lymphocyte infusions have also been
used to demonstrate the principle of graft-vs-autoimmune
effect.44,57,60 Some patients clearly benefited from the
procedure, despite substantial overall toxicity. It is unclear
whether a prospective trial can ever be successfully
completed in this area, but harmonising the procedures
through a prospective non-interventional international
protocol is warranted.
Only anecdotal data are available in SSc, SLE, RA and
vasculitis,197–202 precluding any conclusions or recommen-
dations. Given the high risk of TRM and also potential
chronic reduction in QoL, previous consensus has discour-
aged allogeneic HSCT outside of a clinical trial.59
Recommendations
 Centres performing donor HSCT for ADs should have
appropriate JACIE accreditation or equivalent (level II).
 Syngeneic HSCT may be considered as an alternative to
autologous HSC, with comparable risks and potential
greater benefit. Donor-related issues are an important
consideration (level II).
 Allogeneic HSCT outside of a clinical trial is highly
discouraged in all ADs. In exceptional circumstances,
allogeneic HSCT may be considered for patients with
ITP, AIHA and Evans’ syndrome refractory to at least
two lines of treatment (including rituximab and TPO
receptor agonists for ITP) under the ‘CO’ criterion
(Tables 2a and b) (level III).
 In adults under 50 years with life-threatening auto-
immune cytopenia, allogeneic HSCT may be considered
if an HLA-identical sibling donor is available. In patients
for whom no donor can be identified, autologous HSCT
is preferred over alternative donor HSCT (level III).
 In paediatric patients with life-threatening autoimmune
cytopenia, allogeneic HSCT may be considered if an
HLA-identical sibling donor is available. In Evans’
syndrome, unrelated/alternative donor HSCT from a
well-matched unrelated donor (with at least 9/10
compatible loci by 4 digit/allele high-resolution typing)
may be considered (level III).
 BM or umbilical cord blood is recommended as graft source
for allogeneic HSCT in autoimmune cytopenia (level II).
 Recommended conditioning for HLA-matched sibling
HSCT is with CY 120mg/kg, fludarabine 150mg/kg and
ATG (or other anti-T-cell serotherapy) (level III).
 In the paediatric unrelated/alternative donor setting,
a sufficiently immunosuppressive regimen should be
selected by the responsible clinician. Based on other
areas of paediatric HSCT (metabolic disorders and
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haemoglobinopathies), fludarabine 4 35mg/m2, thiote-
pa 10mg/kg and melphalan 140mg/m2þATG is
one option. Decision making should be individualized
based on local experience and donor/recipient factors
(level III).
Conclusions and future directions
There is now well 15 years of clinical experience of HSCT in
patients with various severe ADs. The field has brought about
fruitful multidisciplinary collaborations to address one of the
most challenging of groups of patients in clinical practice. In
parallel, scientific studies have started to elucidate mechan-
isms of reset and control of dysfunctional immune systems.
However, the evolving industry of biological and small-
molecule drugs has proved a constant challenge to establish-
ing the role of HSCT in severe AD. Only when efficacy is
formally demonstrated by controlled studies balancing the
acute risks of HSCT vs the toxicity of chronic immunosup-
pressive treatment will HSCT be perceived as an alternative
to, or reasonable escalation step after failure of standard
treatment. Lessons previously learnt from the inability to
demonstrate benefit of autologous HSCT in breast cancer16
are pertinent to HSCT for ADs, although the rarity and
heterogeneity of AD warrants a challenging and pragmati-
cally balanced approach. Long-term outcomes of efficacy and
‘late effects’75–77,109,203 are also of major importance, and
health economic considerations should be central to the
development of therapeutic strategies.92 Ultimately, novel
biological, HSCT and other cellular therapy-based ap-
proaches should not be mutually exclusive, and optimal
outcomes may be achieved with combinations of intensive
treatments combined with long-term consolidation and
maintenance approaches. For the present time, it is intended
that these guidelines and recommendations will promote
patient safety and facilitate harmonisation of procedural
aspects, patient selection, data collection and coordination of
prospective studies, with the aim of identifying the most
appropriate clinical niche of HSCT in each AD, as well as
supporting basic scientific research endeavours.
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